When doctors look for ways to fight COVID-19, they often test combinations of different drugs to see if they work better together. This study looked at how favipiravir performed when given alongside lopinavir and ritonavir. Researchers wanted to see if this specific mix could help clear the virus from the body.
The results showed that the combination did not improve the model for antiviral activity. While the drugs interacted in an unexpected way, they did not show a measurable effect on the rate of death for infected cells at the doses tested. The study also found no clear signs of mutations in the viral genome after treatment.
Because the trial was still in an early phase, there are some gaps in what we know. For example, researchers do not yet know the exact reason why these two drugs interacted the way they did. Most importantly, the study confirmed that favipiravir did not show antiviral activity at the specific dose used during this trial.
